Farmakodinamika Ovaj proizvod je acetanilidni antipiretički analgetici. Kroz inhibiciju ciklooksigenaze, selektivne inhibicije hipotalamičke termoregulacije sinteze centralne prostaglandina, što dovodi do periferne vaskularne dilatacije, znojenja i antipiretičkog efekta, aspiritni efekt i aspirin sličan; Inhibicijom sinteze prostaglandina i drugih i oslobađanja poboljšavaju prag boli i igraju analgetski učinak, su periferni analgetici, uloga aspirina nego slaba, samo blaga do umjerenog bola. Ovaj proizvod nema očigledan protuupalni učinak.
Farmakokinetika Nakon oralne uprave gastrointestinalnog trakta iz gastrointestinalnog trakta, u potpunosti (nakon visokog ugljikohidrata može smanjiti apsorpciju), apsorbirana u tijelu nakon distribucije uniforme, oko 25% i obvezujući protein u plazmi. Mali iznos (koncentracija krvi<60μg / ml) and protein binding is not obvious, a large number or a large amount of poisoning rate is higher, up to 43%. 90 ~ 95% of the goods in the liver metabolism, mainly with glucuronic acid, sulfuric acid and cysteine binding. The intermediate metabolites have toxic effects on the liver. Half-life β is generally 1 to 4 hours (2 hours on average), renal insufficiency, but in some patients with liver disease may be extended, the elderly and newborns may be extended, children are shortened. 0.5 to 2 hours after oral administration of plasma concentration up to the peak, the dose of 650mg or less when the plasma concentration of 5 ~ 20μg / ml, the duration of 3 to 4 hours. Lactation during the women taking the goods 650mg, 1 to 2 hours reported milk concentration of 10 ~ 15μg / ml; half-life β is 1.35 ~ 3.5 hours. The goods mainly with glucuronic acid in the form of excretion from the kidneys, about 24 hours within about 3% with the original shape with the urine.
